Germany's Merck KGaA is buying U.K. gene-silencing biotech for $1.3 billion
- U.K. 近 90 天出现 39 次
- 上一次：同一天稍早 · Microsoft pulled out of a U.K. data center deal, clouding Nscale's IPO hopes
发生了什么
The all-cash deal adds divesiran, an experimental rare-disease drug ready for late-stage trials, to Merck's pipeline
摘要按规则整理自下方来源原文